Loading market dashboard
Novartis AG
NVSHealthcareNYSECH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.
Basel, June 4, 2026 – Novartis reported final 2.5-year Phase III ALIGN results showing slower kidney function decline with Vanrafia® (atrasentan) versus placebo in adults with IgA nephropathy (IgAN)1 ,2. Results were published in The Lancet and presented at the European Renal Association (ERA) Congress. Estimated glomerular filtration rate (eGFR) change from baseline favored Vanrafia, alongside sustained reductions of protein in the urine through end of treatment. Benefits were consistent across different measures of kidney function and in patients additionally receiving sodium-glucose co-transporter-2 (SGLT2) inhibitors1,2. “These results provide robust evidence of clinically meaningful slowing of kidney function decline over more than two years of treatment, reinforcing findings from the earlier analysis of proteinuria reduction,” said Richard Lafayette, MD, FACP, Professor of Medicine, Nephrology, Director of the Glomerular Disease Center at Stanford University Medical Center, and ALIGN Study Investigator and Steering Committee Member. “They highlight the role of a highly selective endothelin A receptor antagonist as part of an evolving treatment approach for IgAN.”
Basel, June 3, 2026 – Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained remission rates vs placebo and significant steroid sparing8. Published in the New England Journal of Medicine and simultaneously presented at the 2026 European Alliance of Associations for Rheumatology (EULAR) Congress, Phase III REPLENISH data showed that the effect of Cosentyx treatment was sustained through week 52 in this investigational use8.
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on June 3-6 in London, advancing scientific insight into high-burden autoimmune diseases.
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC; androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). These PSMAddition data were presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.
Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.
On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash for a drug developer, and represents the second largest ever fundraise for a biotech company behind only Altos Labs, according to trade publication Endpoints News.
Investors need to pay close attention to NVS stock based on the movements in the options market lately.
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research. The start of construction on the company's first Texas‑based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide. “Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.” This expansion reinforces Novartis' leadership as the first company to deliver RLT at scale, building the network capacity needed as these therapies extend into earlier stages of treatment and a broader range of cancers. Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality, and operations, supporting economic growth in Denton and surrounding communities. US Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the US Ralf Heckner, Texas State Senator Brent Hagenbuch, Texas State Representative Andy Hopper, and Denton Mayor Gerard Hudspeth joined Novartis leadership, employees, and community partners to celebrate the start of construction. “I'm pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.” The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company's longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical to delivering treatment as planned. In April 2025, Novartis committed $23 billion over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company's broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines. The Denton groundbreaking builds on rapid progress across Novartis' US investment plan.
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
On April 30, 2026, Novartis AG (NVS) shares rose 3.4% today, bringing the current price to $147.85. This price is within a 52-week range of $104.93 to $170.46,
Concurrent Investment Advisors LLC raised its holdings in shares of Novartis AG (NYSE: NVS) by 36.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,815 shares of the company's stock after buying an additional 3,967 shares during the quarter.
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giants have recently said that Europe risks losing out on new medicines as drug prices in the U.S. market are tied to lower prices elsewhere under Trump's MFN policy.
Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way.
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugmaker declined about 3% in premarket trading on Tuesday following the earnings release.
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
European stocks are expected to open higher on Tuesday as investors assess the latest developments in the Iran war, and look ahead to earnings reports.
Swiss drugmaker Novartis reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed on sales.
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc 1 , -1% USD), as growth drivers were more than offset by US generic erosion Continued strong performance from priority brands including Kisqali (+55% cc), Pluvicto (+70% cc), Kesimpta (+26% cc), Scemblix (+79% cc) and Leqvio (+69% cc) Core operating income 1 down -14% (cc, -12% USD), due to lower net sales and higher R&D investment Core operating income margin1 was 37.3% Operating income declined -11% (cc, -9% USD); net income down -13% (cc, -13% USD) Core EPS 1 declined -15% (cc, -13% USD) to USD 1.99 Free cash flow 1 was USD 3.3 billion, broadly in line with the prior-year quarter Q1 selected innovation milestones: Remibrutinib positive CHMP opinion for CSU, positive Phase III readout in CIndU and Phase II data in food allergy Ianalumab FDA Breakthrough Therapy designation and priority review in SjD Cosentyx FDA approval for pediatric HS patients, regulatory submissions for PMR Fabhalta positive Phase III eGFR results in IgAN, FDA priority review for traditional approval Completed acquisition of Avidity, adding three late-stage medicines addressing neuromuscular disease Full year 2026 guidance 2 reaffirmed Net sales expected to grow low single-digit and core operating income expected to decline low single-digit Basel, April 28, 2026 – Commenting on Q1 2026 results, Vas Narasimhan, CEO of Novartis, said: “Novartis delivered a strong start to 2026 across our priority brands and launches, while US generic erosion weighed on results in Q1 as expected.
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a) levels are almost entirely genetically determined, making them a prime target for drugmakers.
Novartis has received European Commission approval for its drug Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU), the Swiss drugmaker said on Monday.
Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment. Rhapsido is the first oral targeted treatment approved for CSU, offering a unique approach to CSU treatment in a pill taken twice daily without any lab monitoring required1.
Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Itvisma® (intrathecal onasemnogene abeparvovec). The opinion supports its use for the treatment of children two years and older, teens, and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.
Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines for Malaria Venture (MMV).
East Hanover, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms. The decision is a key step towards enabling widespread access through public sector procurement. Coartem Baby is also known as Riamet® Baby in some countries and was developed in collaboration with Medicines for Malaria Venture (MMV).
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Evergreen Capital Management LLC boosted its stake in Novartis AG (NYSE: NVS) by 68.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,245 shares of the company's stock after acquiring an additional 19,155 shares during the period. Evergreen Capital
Novartis AG ended 2025 on a high note. On February 27, NVS stock reached a 52-week high of $170.46. However, a correction began after that, in my view, partly due to a 33.2% quarter-over-quarter decline in sales of heart failure drug Entresto to $1.25 billion in Q4.
Merck's outlook is bright despite challenges to its core franchises. Novartis is performing well despite a recent major patent cliff.
Farther Finance Advisors LLC raised its holdings in Novartis AG (NYSE: NVS) by 87.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 34,378 shares of the company's stock after purchasing an additional 16,069 shares during the quarter. Farther Finance Advisors
BOSTON--(BUSINESS WIRE)--Instem announces the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer to lead Instem's scientific and AI strategy.
Novartis AG (NYSE: NVS - Get Free Report) has received a consensus rating of "Hold" from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and one has given a
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.
Anthropic on Tuesday added Novartis' Chief Executive Officer Vas Narasimhan to its board of directors, making him the first executive from the pharmaceutical industry to join the AI startup's governing body.
The startup behind the popular Claude chatbot and coding tool is eyeing a potential IPO as soon as this year.
Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:
East Hanover, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries.1 Three distinct Novartis community health approaches focused on closing gaps in care for low-income, rural and other communities will nearly triple from 11 to more than 30 countries by 2030, including:
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Eldred Rock Partners LLC reduced its position in shares of Novartis AG (NYSE: NVS) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,549 shares of the company's stock after selling 9,204 shares during the period. Novartis makes
Boston Common Asset Management LLC decreased its stake in shares of Novartis AG (NYSE: NVS) by 8.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,266 shares of the company's stock after selling 10,970 shares during the
Euro Pacific Asset Management LLC lessened its holdings in shares of Novartis AG (NYSE: NVS) by 54.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,231 shares of the company's stock after selling 49,536 shares during the quarter. Euro Pacific Asset Management
Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo1. Fabhalta consistently outperformed placebo across key kidney outcomes over two years, demonstrating a slowing of disease progression and the potential to preserve kidney function in IgAN1. The results were published in the New England Journal of Medicine and simultaneously presented as late‑breaking data at the 2026 World Congress of Nephrology (WCN).
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for allergic diseases. Under the agreement, Novartis will pay up to US$2 billion in upfront and milestone payments for Excellergy.
Expense, risk, and sector focus set these two ETFs apart-see which aligns better with your global investing strategy.
Novartis (NVS, Financials) agreed to buy Excellergy, a biotech company located in the U.S., for up to $2 billion. This is part of a string of recent investments
Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pikavation Therapeutics for up to $3 billion to secure the rights to an experimental breast cancer drug.
Novartis AG (ADR) (NYSE:NVS) announced an agreement to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for...
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
